




WHAT IS CLAIMED IS:

1. A compound of the Formula A




wherein R' and R'' are independently selected for each position capable of substitution from the group consisting of halogen, hydroxyl, hydrogen, C₁-C₃ alkoxy, cyano (CN), and nitro (NO₂);


X is chosen from the group consisting of (C=O); O, NH, S, ()
and ()

n is an integer from 1-6; and pharmaceutically acceptable salts thereof.


2. The compound according to claim 1 of the Formula B



3. The compound according to claim 2 of Formula C




4. The compound according to claims 2 or 3 wherein R' is NO₂.
5. The compound according to claims 1-3 or 4 wherein X is chosen from




6. The compound according to claims 1-4 or 5 wherein n is 2, 3 or 4.

7. A compound of the Formula D




wherein R''' is independently selected for each position capable of substitution or from the group consisting of halogen, hydroxyl, hydrogen, C₁-C₃ alkoxy, cyano (CN) and nitro (NO₂);

Y is chosen from the group consisting of , O, NH, S,




m is an integer from 1-6; and pharmaceutically acceptable salts thereof.


8. The compound according to claim 7 of the Formula E




9. The compound according to claim 8 of the Formula F




10. The compound according to claim 7 of the Formula G



11. The compound according to claim 10 of the Formula H




12. A compound having the Formula I




wherein R is selected from the group consisting of H, OH, CN and NO₂; and pharmaceutically acceptable salts thereof.

13. A compound having the Formula J




wherein R is selected from the group consisting of H, OH, CN and NO₂ and pharmaceutically acceptable salts thereof.

14. A compound having the Formula K




wherein R is selected from the group consisting of H, OH, CN and NO₂ and pharmaceutically acceptable salts thereof.

15. A compound having the Formula L




and pharmaceutically acceptable salts thereof.

16. A compound having the Formula M




and pharmaceutically acceptable salts thereof.

17. A compound having the Formula N




and pharmaceutically acceptable salts thereof.

18. A compound having the Formula O




wherein R is selected from the group consisting of H, NO₂, OH, and CN and pharmaceutically acceptable salts thereof.

19. A compound having the Formula P




and pharmaceutically acceptable salts thereof.

20. A compound having the Formula Q




and pharmaceutically acceptable salts thereof.

21. A compound having the Formula R



wherein R is chosen from the group consisting of H, OH, CN and NO₂ and pharmaceutically acceptable salts thereof.

22. A compound of the Formula S




wherein R is chosen from the group consisting of OH, CN and NO₂;

R' is chosen from the group consisting of H, C₁₋₆ alkyl and C₂₋₆ alkenyl;


R'' is chosen independently for each position capable of substitution from the group consisting of H, C₁₋₆ alkyl, halogen, hydroxyl, nitro and cyano; and enantiomers and diastereomers thereof and pharmaceutically acceptable salts thereof.

23. The compound according to claim 22 wherein R' is chosen from the

group consisting of H, CH₃ and 


24. The compound according to claim 22 wherein R'' is chosen from the group consisting of H and CH₃.

25. A compound of the Formula T




wherein R is selected from the group consisting of H and C₁₋₆ alkyl;
 R' and R'' are each independently selected from the group consisting of H, OH, CN and NO₂ with the proviso that R' = R'' ≠ H
 and enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

26. A compound of the Formula U



wherein R is selected from the group consisting of H and C₁₋₆ alkyl;
 R' and R'' are each independently selected from the group consisting of H, OH, NO₂ and CN with the proviso that R' = R'' ≠ H and enantiomers and pharmaceutically acceptable salts thereof.


27. A compound of the Formula V



wherein R is selected from the group consisting of H and C₁₋₆ alkyl

R' and R'' are each independently selected from the group consisting of H, OH, NO₂ and CN with the proviso that R' = R'' ≠ H; and enantiomers and diastereomers and pharmaceutically acceptable salts thereof.


28. A compound of the Formula W



wherein R is selected from the group consisting of H and C₁₋₆ alkyl;

R' and R'' are each independently selected from the group consisting of H, OH, CN and NO₂ with the proviso that R' ≠ R'' ≠ H and enantiomers and diastereomers thereof and pharmaceutically acceptable salts thereof.

29. A compound of the Formula X




wherein R is selected from the group consisting of OH, NO₂ and CN;

R' is selected from the group consisting of H and C₁₋₃ alkyl;

R'' is selected independently for each position capable of substitution from the group consisting of halogen, hydroxyl, hydrogen, C₁₋₃ alkyl, cyano and nitro; n is 0-6 and enantiomers and diastereomers thereof and pharmaceutically acceptable salts thereof.

30. The compound according to claim 29 wherein having the Formula Y



31. The compound according to claims 29 or 30 wherein n is 2.

32. The compound according to claims 29-30 or 31 wherein R' is H.

33. A pharmaceutical composition comprising one or more compounds according to claims 1-31 or 32 in a therapeutically effective amount and in combination with one or more pharmaceutically acceptable carriers or diluents.

34. A method of treatment of Parkinson's, Disease Tourett's syndrome, Cognitive impairment depression, Alzheimer's disease, senile dementia, anxiety disorders, ischemic disease states, obsessive compulsive disorder, migraine, amyotrophic lateral sclerosis, epilepsy, eating disorders, premenstrual syndrome, attention deficit hyperactivity disorders, bipolar disorders, sexual dysfunction, and psychoses comprising administering to a patient in need of said treatment a pharmaceutical composition according to claim 33.

35. A method for the treatment of schizophrenia comprising administering to a patient in need of said treatment a pharmaceutical composition according to claim 33.

36. A method for the treatment of the positive symptoms of schizophrenia comprising administering to a patient in need of such treatment a pharmaceutical composition according to claim 33.

37. A method for the treatment of the negative symptoms of schizophrenia comprising administering to a patient in need of such treatment a pharmaceutical composition according to claim 33.